thalidomide has been researched along with Hematologic Malignancies in 46 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is a synthetic analog of thalidomide formed by the removal of one keto group (plus the addition of an amino group); it has anti-tumor activities beneficial for the treatment of hematologic malignancies." | 8.12 | Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. ( Ando, K; Kamiya, Y; Machida, S; Murayama, N; Ogiya, D; Saito, R; Shiraiwa, S; Suzuki, R; Tazume, K; Yamazaki, H, 2022) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, which has pleotropic activity, including antiangiogenic and antineoplastic properties." | 6.44 | The evolving role of lenalidomide in the treatment of hematologic malignancies. ( Dimopoulos, MA; Kastritis, E, 2007) |
| "Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents." | 5.32 | Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003) |
| "Lenalidomide (LEN) has emerged as a promising therapeutic option for the management of various hematologic malignancies." | 5.16 | Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. ( Benath, G; Bornhäuser, M; Ehninger, G; Ferrer, RA; Hofbauer, LC; Platzbecker, U; Rauner, M; Schmitz, M; Wehner, R; Wobus, M, 2012) |
| "Thalidomide and its derivatives represent a new class of antineoplastic drugs (IMiDs), which has been especially effective in certain hematologic malignancies." | 4.85 | Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). ( Wiernik, PH, 2009) |
| " Thalidomide which has antiangiogenic effects and direct cytotoxic effects was found to be effective in multiple myeloma and is considered as an established treatment modality for patients with refractory or relapsed multiple myeloma." | 4.82 | Antiangiogenic therapy in hematologic malignancies. ( Goldschmidt, H; Hillengass, J; Ho, AD; Moehler, TM, 2004) |
| "Lenalidomide is a synthetic analog of thalidomide formed by the removal of one keto group (plus the addition of an amino group); it has anti-tumor activities beneficial for the treatment of hematologic malignancies." | 4.12 | Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. ( Ando, K; Kamiya, Y; Machida, S; Murayama, N; Ogiya, D; Saito, R; Shiraiwa, S; Suzuki, R; Tazume, K; Yamazaki, H, 2022) |
| "Longer survival in patients with multiple myeloma (MM) after treatment with novel agents (NA) such as thalidomide, bortezomib, and lenalidomide may be associated with increased risks of developing second primary malignancies (SPM)." | 3.96 | Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan. ( Hou, HA; Liu, Y; Qiu, H; Tang, CH, 2020) |
| "Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma." | 2.61 | IMiDs New and Old. ( Ruan, J; Yamshon, S, 2019) |
| "We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
| "Lenalidomide is an immunomodulatory, antiangiogenic drug that is a structural analog of thalidomide." | 2.48 | [Lenalidomide in hematological malignancies---review]. ( Jin, X; Zhang, YZ, 2012) |
| "Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that has emerged as a drug with activity against various hematological and solid malignancies." | 2.48 | [Action mechanism of lenalidomide in hematological malignancies - review]. ( Liu, LR; Qian, SX, 2012) |
| "In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma." | 2.47 | Exploring old drugs for the treatment of hematological malignancies. ( Cao, B; Chen, Z; Gan, F; Hou, T; Mao, X; Wu, D, 2011) |
| "Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies." | 2.45 | Mechanism of action of lenalidomide in hematological malignancies. ( Das, B; Goel, S; Heuck, C; Kotla, V; Nischal, S; Verma, A; Vivek, K, 2009) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, which has pleotropic activity, including antiangiogenic and antineoplastic properties." | 2.44 | The evolving role of lenalidomide in the treatment of hematologic malignancies. ( Dimopoulos, MA; Kastritis, E, 2007) |
| "Thalidomide is an immunomodulatory and antiangiogenic drug." | 2.42 | Thalidomide: from tragedy to promise. ( Cerny, T; Gillessen, S; Stolz, R; von Moos, R, 2003) |
| " As a result of adverse effects, salvage therapy had to be discontinued or reduced in 14 patients (26%)." | 2.42 | Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center. ( Berlanga, J; Büchler, T; Encuentra, M; Ferra, C; Gallardo, D; Grañena, A; Hermosilla, M; Sarra, J, 2003) |
| "Angiogenesis in Patients with Hematologic Malignancies The importance of angiogenesis for the progressive growth and viability of solid tumors is well established." | 2.41 | [Angiogenesis in patients with hematologic malignancies]. ( Berdel, WE; Bieker, R; Kessler, T; Kienast, J; Mesters, RM; Padró, T; Retzlaff, S; Steins, M, 2001) |
| "Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s." | 2.41 | Thalidomide: an old sedative-hypnotic with anticancer activity? ( Alberti, AM; Capaccetti, B; Gasparini, G; Gattuso, D; Magnani, E; Morabito, A, 2001) |
| "Lenalidomide is an antiangiogenic drug associated with hypothyroidism." | 1.37 | Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. ( Brown, K; Clayton, W; Figaro, MK; Jagasia, S; Kassim, A; Lakhani, VT; Usoh, C, 2011) |
| "Lenalidomide has significant activity in myelodysplastic syndromes, multiple myeloma, and non-Hodgkin's lymphoma (NHL)." | 1.35 | lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. ( Adams, M; Bartlett, JB; Carter, T; Chen, R; Muller, G; Schafer, P; Stirling, D; Wu, L, 2008) |
| "Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents." | 1.32 | Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (45.65) | 29.6817 |
| 2010's | 20 (43.48) | 24.3611 |
| 2020's | 5 (10.87) | 2.80 |
| Authors | Studies |
|---|---|
| Certan, M | 1 |
| Garcia Garrido, HM | 1 |
| Wong, G | 1 |
| Heijmans, J | 1 |
| Grobusch, MP | 1 |
| Goorhuis, A | 1 |
| Ogiya, D | 1 |
| Murayama, N | 1 |
| Kamiya, Y | 1 |
| Saito, R | 1 |
| Shiraiwa, S | 1 |
| Suzuki, R | 1 |
| Machida, S | 1 |
| Tazume, K | 1 |
| Ando, K | 1 |
| Yamazaki, H | 1 |
| Bunce, CM | 1 |
| Khanim, FL | 1 |
| Drayson, MT | 1 |
| Liu, Y | 1 |
| Hou, HA | 1 |
| Qiu, H | 1 |
| Tang, CH | 1 |
| Renneville, A | 1 |
| Gasser, JA | 2 |
| Grinshpun, DE | 1 |
| Jean Beltran, PM | 1 |
| Udeshi, ND | 2 |
| Matyskiela, ME | 1 |
| Clayton, T | 1 |
| McConkey, M | 1 |
| Viswanathan, K | 1 |
| Tepper, A | 1 |
| Guirguis, AA | 1 |
| Sellar, RS | 2 |
| Cotteret, S | 1 |
| Marzac, C | 1 |
| Saada, V | 1 |
| De Botton, S | 1 |
| Kiladjian, JJ | 1 |
| Cayuela, JM | 1 |
| Rolfe, M | 1 |
| Chamberlain, PP | 1 |
| Carr, SA | 2 |
| Ebert, BL | 2 |
| Scharenberg, C | 1 |
| Jansson, M | 1 |
| Saft, L | 1 |
| Hellström-Lindberg, E | 1 |
| Sperling, AS | 1 |
| Burgess, M | 1 |
| Keshishian, H | 1 |
| Bhatt, S | 1 |
| Jan, M | 1 |
| Słabicki, M | 1 |
| Fink, EC | 1 |
| Miller, PG | 1 |
| Liddicoat, BJ | 1 |
| Sievers, QL | 1 |
| Sharma, R | 1 |
| Adams, DN | 1 |
| Olesinski, EA | 1 |
| Fulciniti, M | 1 |
| Kuhn, E | 1 |
| Letai, A | 1 |
| Munshi, NC | 1 |
| Yamshon, S | 1 |
| Ruan, J | 1 |
| Su, S | 1 |
| Yang, Z | 1 |
| Gao, H | 1 |
| Yang, H | 1 |
| Zhu, S | 1 |
| An, Z | 1 |
| Wang, J | 1 |
| Li, Q | 1 |
| Chandarlapaty, S | 1 |
| Deng, H | 1 |
| Wu, W | 1 |
| Rao, Y | 1 |
| Xu, M | 1 |
| Hou, Y | 1 |
| Sheng, L | 1 |
| Peng, J | 1 |
| Vij, R | 1 |
| Manabe, M | 1 |
| Okita, J | 1 |
| Tarakuwa, T | 1 |
| Harada, N | 1 |
| Aoyama, Y | 1 |
| Kumura, T | 1 |
| Ohta, T | 1 |
| Furukawa, Y | 1 |
| Mugitani, A | 1 |
| Asakura, H | 1 |
| Li, KD | 1 |
| Salama, ME | 1 |
| Chen, N | 1 |
| Zhou, S | 1 |
| Palmisano, M | 1 |
| Wu, L | 1 |
| Adams, M | 1 |
| Carter, T | 1 |
| Chen, R | 1 |
| Muller, G | 1 |
| Stirling, D | 1 |
| Schafer, P | 1 |
| Bartlett, JB | 1 |
| Wiernik, PH | 1 |
| Kotla, V | 1 |
| Goel, S | 1 |
| Nischal, S | 1 |
| Heuck, C | 1 |
| Vivek, K | 1 |
| Das, B | 1 |
| Verma, A | 1 |
| Sze, DM | 1 |
| Chan, GC | 1 |
| Oh, ST | 1 |
| Gotlib, J | 1 |
| Li, S | 1 |
| Gill, N | 1 |
| Lentzsch, S | 1 |
| Gan, F | 1 |
| Cao, B | 1 |
| Wu, D | 1 |
| Chen, Z | 1 |
| Hou, T | 1 |
| Mao, X | 1 |
| Figaro, MK | 1 |
| Clayton, W | 1 |
| Usoh, C | 1 |
| Brown, K | 1 |
| Kassim, A | 1 |
| Lakhani, VT | 1 |
| Jagasia, S | 1 |
| Wémeau, M | 1 |
| Gauthier, J | 1 |
| Leleu, X | 1 |
| Yakoub-Agha, I | 1 |
| Podar, K | 1 |
| Anderson, KC | 1 |
| Pashos, CL | 1 |
| Cragin, LS | 1 |
| Khan, ZM | 1 |
| Jin, X | 1 |
| Zhang, YZ | 1 |
| Wobus, M | 1 |
| Benath, G | 1 |
| Ferrer, RA | 1 |
| Wehner, R | 1 |
| Schmitz, M | 1 |
| Hofbauer, LC | 1 |
| Rauner, M | 1 |
| Ehninger, G | 1 |
| Bornhäuser, M | 1 |
| Platzbecker, U | 1 |
| Bayraktar, UD | 1 |
| Bashir, Q | 1 |
| Qazilbash, M | 1 |
| Champlin, RE | 1 |
| Ciurea, SO | 1 |
| Liu, LR | 1 |
| Qian, SX | 1 |
| von Moos, R | 1 |
| Stolz, R | 1 |
| Cerny, T | 1 |
| Gillessen, S | 1 |
| Gordon, JN | 1 |
| Goggin, PM | 1 |
| Büchler, T | 1 |
| Hermosilla, M | 1 |
| Ferra, C | 1 |
| Encuentra, M | 1 |
| Gallardo, D | 1 |
| Berlanga, J | 1 |
| Sarra, J | 1 |
| Grañena, A | 1 |
| Fanelli, M | 1 |
| Sarmiento, R | 1 |
| Gattuso, D | 2 |
| Carillio, G | 1 |
| Capaccetti, B | 2 |
| Vacca, A | 3 |
| Roccaro, AM | 2 |
| Gasparini, G | 2 |
| Kulkarni, S | 1 |
| Powles, R | 1 |
| Sirohi, B | 1 |
| Treleaven, J | 1 |
| Saso, R | 1 |
| Horton, C | 1 |
| Atra, A | 1 |
| Ortin, M | 1 |
| Rudin, C | 1 |
| Goyal, S | 1 |
| Sankpal, S | 1 |
| Meller, S | 1 |
| Pinkerton, CR | 1 |
| Mehta, J | 1 |
| Singhal, S | 1 |
| Moehler, TM | 1 |
| Hillengass, J | 1 |
| Goldschmidt, H | 1 |
| Ho, AD | 1 |
| Ribatti, D | 2 |
| Scavelli, C | 1 |
| Crivellato, E | 1 |
| Nico, B | 1 |
| Boehrer, S | 1 |
| Nowak, D | 1 |
| Hoelzer, D | 1 |
| Mitrou, PS | 1 |
| Chow, KU | 1 |
| Ferreri, AJ | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Poreba, M | 1 |
| Kuliczkowski, K | 1 |
| Kastritis, E | 1 |
| Dimopoulos, MA | 1 |
| Ludwig, H | 1 |
| Strasser-Weippl, K | 1 |
| Schreder, M | 1 |
| Zojer, N | 1 |
| Rajkumar, SV | 1 |
| Mesters, RM | 1 |
| Padró, T | 1 |
| Steins, M | 1 |
| Bieker, R | 1 |
| Retzlaff, S | 1 |
| Kessler, T | 1 |
| Kienast, J | 1 |
| Berdel, WE | 1 |
| Morabito, A | 1 |
| Magnani, E | 1 |
| Alberti, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab[NCT00783367] | Phase 2 | 50 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| A Prospective Single-center Study on the Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS[NCT06004765] | Phase 4 | 138 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate is defined as a complete response or partial response using anatomic criteria of the International Workshop Response Critieria (Cheson, 1999). (NCT00783367)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 14 |
| Cohort 2 | 13 |
Progression free survival time in months (NCT00783367)
Timeframe: 9 years from enrollment of first subject
| Intervention | months (Median) |
|---|---|
| Cohort 1 | 22.2 |
| Cohort 2 | 22.4 |
31 reviews available for thalidomide and Hematologic Malignancies
| Article | Year |
|---|---|
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; | 2022 |
IMiDs New and Old.
Topics: Animals; Antineoplastic Agents; Biomarkers; Disease Susceptibility; Drug Resistance, Neoplasm; Hemat | 2019 |
Therapeutic effects of thalidomide in hematologic disorders: a review.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Graft vs Host Disease; Hematologic Neoplasms; Hum | 2013 |
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
[Thrombosis and DIC in hematological malignancies].
Topics: Annexin A2; Antineoplastic Agents; Asparaginase; Cytokines; Disseminated Intravascular Coagulation; | 2014 |
Therapy Effect: Impact on Bone Marrow Morphology.
Topics: Antineoplastic Agents; Atrophy; Bone Marrow; Cytokines; Hematologic Neoplasms; Humans; Imatinib Mesy | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.
Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Hematologic Neoplasms; | 2017 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Mechanism of action of lenalidomide in hematological malignancies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pa | 2009 |
Supplements for immune enhancement in hematologic malignancies.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Glucans; Child; Clinical T | 2009 |
Recent advances of IMiDs in cancer therapy.
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Immunologic Factor | 2010 |
Exploring old drugs for the treatment of hematological malignancies.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Drug Repositioning; Hematologic Neoplasms; Humans; T | 2011 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoi | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; I | 2011 |
[Lenalidomide in hematological malignancies---review].
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Myelodysplas | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2013 |
[Action mechanism of lenalidomide in hematological malignancies - review].
Topics: Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Thalidomide | 2012 |
Thalidomide: from tragedy to promise.
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; History, 20th Century; Humans; Immunosuppressive Age | 2003 |
Thalidomide and its derivatives: emerging from the wilderness.
Topics: Adjuvants, Immunologic; Cachexia; Crohn Disease; Graft vs Host Disease; Hematologic Neoplasms; Human | 2003 |
Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Disease Progression; Dis | 2003 |
Thalidomide: a new anticancer drug?
Topics: Animals; Antineoplastic Agents; Cachexia; Hematologic Neoplasms; Humans; Neoplasms; Thalidomide | 2003 |
Antiangiogenic therapy in hematologic malignancies.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple | 2004 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Hema | 2005 |
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apop | 2006 |
[Angiogenesis and endothelial cells in blood neoplasms].
Topics: Angiogenesis Inhibitors; Bone Marrow; Endothelial Cells; Endothelium, Vascular; Growth Substances; H | 2006 |
The evolving role of lenalidomide in the treatment of hematologic malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Hematologic Neoplasms; Humans; Lenalidomide; Leukemia; Myelodysp | 2007 |
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Cli | 2007 |
Current status of thalidomide in the treatment of cancer.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; | 2001 |
[Angiogenesis in patients with hematologic malignancies].
Topics: Aged; Aged, 80 and over; Bone Marrow; Clinical Trials as Topic; Female; Hematologic Neoplasms; Human | 2001 |
Thalidomide: an old sedative-hypnotic with anticancer activity?
Topics: Animals; Antineoplastic Agents; Hematologic Neoplasms; Humans; Neoplasms; Teratogens; Thalidomide | 2001 |
1 trial available for thalidomide and Hematologic Malignancies
| Article | Year |
|---|---|
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells.
Topics: 5'-Nucleotidase; Adipogenesis; Adult; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation | 2012 |
14 other studies available for thalidomide and Hematologic Malignancies
| Article | Year |
|---|---|
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; D | 2022 |
Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies.
Topics: Animals; Cell Membrane Permeability; Female; Hematologic Neoplasms; Humans; Lenalidomide; Multiple M | 2022 |
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bort | 2020 |
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Topics: DNA-Binding Proteins; Hematologic Neoplasms; Humans; Lenalidomide; Oncogene Proteins; Thalidomide; T | 2021 |
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolutio | 2018 |
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.
Topics: Hematologic Neoplasms; Humans; Proteolysis; Substrate Specificity; Thalidomide; Ubiquitin-Protein Li | 2019 |
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 6; Hematologi | 2019 |
Haematological cancer: a step before the next leap?
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; | 2013 |
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity | 2008 |
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity | 2008 |
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity | 2008 |
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity | 2008 |
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic | 2008 |
Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Incidence; Le | 2011 |
Effect of a patient support program on access to oral therapy for hematologic malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Industry; Female; Health | 2012 |
Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Chronic Disease; | 2003 |
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hum | 2006 |